<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386656</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-TRA-2017-02</org_study_id>
    <nct_id>NCT03386656</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery</brief_title>
  <acronym>TRA</acronym>
  <official_title>Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of topical tranexamic acid versus placebo in patients
      diagnosed with severe knee osteoarthritis who will undergo prosthetic knee surgery in terms
      of saving blood loss (estimated blood loss, decreased hemoglobin and Decrease in hematocrit).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the
      fibrinolytic properties of plasmin. Tranexamic acid binds to plasminogen when it is
      transformed into plasmin. The activity of the tranexamic acid-plasmin complex on fibrin
      activity is less than the activity of free plasmin alone.

      There are two methods of presentation: one, as an injectable solution; Two as a clear,
      colorless aqueous solution.

      Tranexamic acid in Spain is approved for use in the prevention and treatment of bleeding due
      to general fibrinolysis. As for its specific indications the investigators find that it is
      used for the treatment of metrorrhagia, menorrhagia, gastrointestinal hemorrhage, urinary
      hemorrhagic disorders after prostate surgery, surgery of ears, nose, throat, gynecological,
      thoracic, abdominal or cardiovascular or to counter associated hemorrhages To the
      administration of a fibrinolytic drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saving blood loss in knee surgery</measure>
    <time_frame>24 hours post-intervention</time_frame>
    <description>Total blood loss greater than 245 ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time post-intervention of functional recovery in study subjects</measure>
    <time_frame>Four weeks post-discharger</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay in study subjects</measure>
    <time_frame>Four weeks post-discharger</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Amchafibrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution 0,9%.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparator of tranexamic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amchafibrin</intervention_name>
    <description>Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.</description>
    <arm_group_label>Amchafibrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline Solution 0,9%.</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes, in the age group: ≥18 and ≤80 years.

          -  Patients diagnosed with confirmation of severe knee osteoarthritis according to
             Kellgren criteria (equal or greater than 2) and EVA greater than 7, who will be
             subjected to knee arthroplasty surgery.

          -  Patients signing informed consent, agreeing to participate in the study.

        Exclusion Criteria:

          -  Patients with concomitant cardiac disease: unstable angina pectoris, acute myocardial
             infarction, atrial fibrillation, flutter, history of sudden death, severe valve
             insufficiency.

          -  Patients with concomitant previous thromboembolic disease: Deep venous thrombosis,
             pulmonary thromboembolism, thrombotic arterial embolism, Ischemic Vascular Cerebral
             Stroke, fibrinolytic diseases after consumption coagulopathy.

          -  Hypersensitivity to tranexamic acid.

          -  Severe systemic disease: cardio-pulmonary, neurological, renal, infectious or any
             other type that may impede the development of the study or evaluation of the results.

          -  History of seizures.

          -  Patients with severe mental disorder (psychotic disorder, risk of autolysis, manic
             episode), dependence on toxic substances and / or some physical or psychological
             limitation to answer.

          -  Patients receiving oral anticoagulants.

          -  Patients in litigation for disability claim related or not with the disease.

          -  Patients who cannot make the necessary visits to carry out the study.

          -  Patients who refuse to participate or sign informed consent.

          -  Pregnant and lactating patient's period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jose antonio andres garcia, MD</last_name>
    <phone>956 00 21 00</phone>
    <email>josea.andres.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María del Mar Benjumea Vargas</last_name>
    <phone>955 040 460</phone>
    <email>gestionensayosclinicos.fps@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Andrés García, MD</last_name>
      <phone>956002100</phone>
      <email>josea.andres.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Tranexamic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

